Anavex Life Sciences Reports Reduced Operating Expenses and Net Losses in Q2 Fiscal 2026

Anavex Life Sciences Corp. reported its financial results for the second quarter of fiscal 2026, revealing a significant reduction in operating expenses and net losses compared to the same period in the previous year. For the three months ended March 31, 2026, the company recorded total operating expenses of $6.5 million, down from $12.5 million in the prior year. This decrease was primarily driven by a reduction in research and development expenses, which fell to $4.2 million from $9.9 million. The net loss for the quarter was $5.3 million, or $0.06 per share, compared to a net loss of $11.2 million, or $0.13 per share, in the same quarter of 2025.

In the six-month period ending March 31, 2026, Anavex's total operating expenses were $13.3 million, a decrease from $26.1 million in the prior year. The company reported a net loss of $11.0 million, or $0.12 per share, compared to $23.3 million, or $0.27 per share, for the same period in 2025. The reduction in losses was attributed to decreased spending on research and development activities, particularly following the completion of the ANAVEX 3-71 clinical trial for schizophrenia and the withdrawal of the Marketing Authorization Application for ANAVEX 2-73.

Anavex's cash position improved significantly, with cash and cash equivalents totaling $127.4 million as of March 31, 2026, compared to $102.6 million at the end of the previous fiscal year. The increase in cash was primarily due to the issuance of 6,026,237 shares of common stock under the 2025 Sales Agreement, generating net proceeds of approximately $36.4 million. The company reported a working capital of $121.7 million, reflecting a strong liquidity position to support ongoing clinical development activities.

Strategically, Anavex is focusing on advancing its lead compound, ANAVEX 2-73 (blarcamesine), for the treatment of mild cognitive impairment due to Alzheimer’s disease and other neurodevelopmental disorders. Following the termination of its former CEO, the company is prioritizing engagement with the U.S. Food and Drug Administration (FDA) to align on a clear regulatory and clinical development strategy. The company has also paused development on other assets, including ANAVEX 3-71, ANAVEX 1-41, and ANAVEX 1066, pending additional funding or strategic partnerships.

Looking ahead, Anavex anticipates continued negative cash flows from operations as it progresses through clinical trials and seeks regulatory approvals. The company has indicated that it will require substantial additional capital to fund its operations and development activities in the foreseeable future. Management remains focused on identifying potential strategic partners and may consider licensing or selling certain assets to enhance its financial position and advance its clinical programs.